F/TAF Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis (TAF4TRANS)
Latest Information Update: 09 May 2023
At a glance
- Drugs Emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Pharmacodynamics
- Acronyms TAF4TRANS
- 02 May 2023 Planned End Date changed from 30 Jun 2022 to 31 Jan 2024.
- 02 May 2023 Planned primary completion date changed from 30 Jun 2022 to 31 Jan 2024.
- 02 May 2023 Status changed from completed to active, no longer recruiting.